Tissue Plasminogen Activator for Acute Ischemic Stroke
To the Editor: In “Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke” (Dec. 14 issue), 1 it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1996-05, Vol.334 (21), p.1405-1406 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1406 |
|---|---|
| container_issue | 21 |
| container_start_page | 1405 |
| container_title | The New England journal of medicine |
| container_volume | 334 |
| creator | Friedman, H S |
| description | To the Editor:
In “Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke” (Dec. 14 issue),
1
it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic conclusion, several methodologic issues and the demonstrated risks of treatment with t-PA suggest a more cautious interpretation. Although the study was randomized, there were important base-line differences that favored the t-PA–treated patients. Overall, more patients in the t-PA–treated group than in the placebo group had been receiving aspirin before the event (odds ratio, 1.697; 95 percent . . . |
| doi_str_mv | 10.1056/NEJM199605233342114 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78007778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78007778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-5e9df3b264c78833a327305d41f76832b755af0f435d9faa24358935bb91409c3</originalsourceid><addsrcrecordid>eNp9kEtLw0AUhQdRaq3-AhGyciPRmdx5LkupWqkPsK6HyWRGUzNJzSSC_95IiyvxwuVeOOd8i4PQKcGXBDN-9TC_uydKccwyAKAZIXQPjQkDSCnFfB-NMc5kSoWCQ3QU4xoPQ6gaoZHkhFIQY8RXZYy9S54qE0NZN6-uTqa2Kz9N17SJH3Zq-84li2jfXCht8ty1zbs7RgfeVNGd7O4EvVzPV7PbdPl4s5hNl6mlSnQpc6rwkGecWiElgIFMAGYFJV5wCVkuGDMeewqsUN6YbHikApbnilCsLEzQ-Za7aZuP3sVOhzJaV1Wmdk0ftZAYCyHkYISt0bZNjK3zetOWwbRfmmD905b-o60hdbbD93lwxW9mV8-gX2z1EKKu3Tr8S_sG8TxvKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78007778</pqid></control><display><type>article</type><title>Tissue Plasminogen Activator for Acute Ischemic Stroke</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Friedman, H S</creator><creatorcontrib>Friedman, H S</creatorcontrib><description>To the Editor:
In “Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke” (Dec. 14 issue),
1
it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic conclusion, several methodologic issues and the demonstrated risks of treatment with t-PA suggest a more cautious interpretation. Although the study was randomized, there were important base-line differences that favored the t-PA–treated patients. Overall, more patients in the t-PA–treated group than in the placebo group had been receiving aspirin before the event (odds ratio, 1.697; 95 percent . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199605233342114</identifier><identifier>PMID: 8614437</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Acute Disease ; Aspirin - therapeutic use ; Cerebrovascular Disorders - drug therapy ; Clinical Protocols ; Humans ; Platelet Aggregation Inhibitors - therapeutic use ; Tissue Plasminogen Activator - adverse effects ; Tissue Plasminogen Activator - therapeutic use</subject><ispartof>The New England journal of medicine, 1996-05, Vol.334 (21), p.1405-1406</ispartof><rights>Copyright © 1996 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-5e9df3b264c78833a327305d41f76832b755af0f435d9faa24358935bb91409c3</citedby><cites>FETCH-LOGICAL-c497t-5e9df3b264c78833a327305d41f76832b755af0f435d9faa24358935bb91409c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199605233342114$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199605233342114$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>315,781,785,2760,2761,26108,27929,27930,52387,54069,64392</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8614437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friedman, H S</creatorcontrib><title>Tissue Plasminogen Activator for Acute Ischemic Stroke</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
In “Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke” (Dec. 14 issue),
1
it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic conclusion, several methodologic issues and the demonstrated risks of treatment with t-PA suggest a more cautious interpretation. Although the study was randomized, there were important base-line differences that favored the t-PA–treated patients. Overall, more patients in the t-PA–treated group than in the placebo group had been receiving aspirin before the event (odds ratio, 1.697; 95 percent . . .</description><subject>Acute Disease</subject><subject>Aspirin - therapeutic use</subject><subject>Cerebrovascular Disorders - drug therapy</subject><subject>Clinical Protocols</subject><subject>Humans</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Tissue Plasminogen Activator - adverse effects</subject><subject>Tissue Plasminogen Activator - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLw0AUhQdRaq3-AhGyciPRmdx5LkupWqkPsK6HyWRGUzNJzSSC_95IiyvxwuVeOOd8i4PQKcGXBDN-9TC_uydKccwyAKAZIXQPjQkDSCnFfB-NMc5kSoWCQ3QU4xoPQ6gaoZHkhFIQY8RXZYy9S54qE0NZN6-uTqa2Kz9N17SJH3Zq-84li2jfXCht8ty1zbs7RgfeVNGd7O4EvVzPV7PbdPl4s5hNl6mlSnQpc6rwkGecWiElgIFMAGYFJV5wCVkuGDMeewqsUN6YbHikApbnilCsLEzQ-Za7aZuP3sVOhzJaV1Wmdk0ftZAYCyHkYISt0bZNjK3zetOWwbRfmmD905b-o60hdbbD93lwxW9mV8-gX2z1EKKu3Tr8S_sG8TxvKg</recordid><startdate>19960523</startdate><enddate>19960523</enddate><creator>Friedman, H S</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960523</creationdate><title>Tissue Plasminogen Activator for Acute Ischemic Stroke</title><author>Friedman, H S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-5e9df3b264c78833a327305d41f76832b755af0f435d9faa24358935bb91409c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Acute Disease</topic><topic>Aspirin - therapeutic use</topic><topic>Cerebrovascular Disorders - drug therapy</topic><topic>Clinical Protocols</topic><topic>Humans</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Tissue Plasminogen Activator - adverse effects</topic><topic>Tissue Plasminogen Activator - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friedman, H S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friedman, H S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tissue Plasminogen Activator for Acute Ischemic Stroke</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1996-05-23</date><risdate>1996</risdate><volume>334</volume><issue>21</issue><spage>1405</spage><epage>1406</epage><pages>1405-1406</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
In “Tissue Plasminogen Activator [t-PA] for Acute Ischemic Stroke” (Dec. 14 issue),
1
it is reported that treatment with t-PA increases a patient's chance of recovering from an ischemic stroke without any, or only minimal, disability or neurologic deficit. Despite this optimistic conclusion, several methodologic issues and the demonstrated risks of treatment with t-PA suggest a more cautious interpretation. Although the study was randomized, there were important base-line differences that favored the t-PA–treated patients. Overall, more patients in the t-PA–treated group than in the placebo group had been receiving aspirin before the event (odds ratio, 1.697; 95 percent . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>8614437</pmid><doi>10.1056/NEJM199605233342114</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1996-05, Vol.334 (21), p.1405-1406 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78007778 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Acute Disease Aspirin - therapeutic use Cerebrovascular Disorders - drug therapy Clinical Protocols Humans Platelet Aggregation Inhibitors - therapeutic use Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - therapeutic use |
| title | Tissue Plasminogen Activator for Acute Ischemic Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T00%3A38%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tissue%20Plasminogen%20Activator%20for%20Acute%20Ischemic%20Stroke&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Friedman,%20H%20S&rft.date=1996-05-23&rft.volume=334&rft.issue=21&rft.spage=1405&rft.epage=1406&rft.pages=1405-1406&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM199605233342114&rft_dat=%3Cproquest_cross%3E78007778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78007778&rft_id=info:pmid/8614437&rfr_iscdi=true |